After enduring a two-year diagnostic odyssey, Gregory Maassen received a diagnosis of a postinfectious form of peripheral ...

As Gregory Maassen, Ph.D., prepares to e-bike more than 5,800 miles across the country, he's using the same sense of adventure and skills that he drew ...

We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate ...

Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...

News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

Neuropathy – chronic pain, numbness and tingling in the hands and feet – is a challenging fact of life for many patients with ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Thanks to a new National Institutes of Health grant, a UCF College of Medicine scientist is investigating a new approach to treat neuropathy without relying on pain pills and anti-depressants.

Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported ...